Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAZX | ISIN: SE0006371126 | Ticker-Symbol: 7V3
Frankfurt
13.11.24
08:06 Uhr
0,133 Euro
-0,005
-3,76 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
5-Tage-Chart
CANTARGIA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1440,18513:37
ACCESSWIRE
417 Leser
Artikel bewerten:
(2)

Cantargia Results Showing Efficacy of CAN10 in Models of Myocarditis Published in Circulation: Heart Failure

Finanznachrichten News

LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced the publication of CAN10 results in disease models of myocarditis in the scientific journal Circulation: Heart Failure. Key results relate to strong treatment effects in both viral as well as autoimmune myocarditis. CAN10, simultaneously targeting IL-1, IL-33 and IL-36, generated much stronger effects than treatment blocking only IL-1. CAN10 is in phase 1 clinical development.

"CAN10 has generated strong preclinical results in models of myocarditis which is a disease with very high medical need. We are pleased that these important results are now published in an impactful scientific journal," said Göran Forsberg, CEO of Cantargia.

The IL1RAP-binding antibody CAN10 has shown strong efficacy in various inflammatory and autoimmune disease models and is now in phase 1 clinical development. The clinical data so far indicate good safety, receptor binding and a potent pharmacodynamic effect counteracting inflammatory immune cell responses in healthy subjects. Currently, safety, pharmacokinetics and biomarker effects are investigated in participants with psoriasis in a multiple ascending dose setting. Phase 2 clinical development is planned to start H2 2025.

Myocarditis is a life-threatening disease characterized by inflammation of the heart muscle and impaired heart function. It may result from autoimmunity or as a side effect to certain pharmaceuticals (including checkpoint inhibitors), but is most commonly caused by viral infections, and rates of myocarditis increased during the COVID-19 pandemic. The data published in Circulation: Heart Failure show potent efficacy of the CAN10 mouse surrogate antibody in in vivo models of both viral and autoimmune myocarditis. Notably, CAN10 counteracted disease development in both models and the treatment effect was much stronger than blockade of IL-1 signaling only. CAN10 counteracted both inflammation in the heart muscle as well fibrosis and preserved heart function. This clearly highlights the unique and powerful function of CAN10, resulting in a broad mode of action which is beneficial in complex inflammatory and fibrotic diseases such as myocarditis. The key results have previously been reported as posters at scientific conferences.

The research has been carried out as collaborations with Prof. Daniela Cihakova at the Johns Hopkins University, Baltimore, MD, USA and Associate Prof. Alexandru Schiopu at Lund University, Sweden. The article by Diego A. Lema et al. can be accessed through the journal's webpage www.ahajournals.org.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

About CAN10

The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: hidradenitis suppurativa (HS) and systemic sclerosis. In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. Up to 80 subjects may be included in the trial. Good safety is shown at the completed dose levels, and additional data from the trial are expected continuously during 2024 and 2025.

Attachments
Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure

SOURCE: Cantargia



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.